Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $30.00

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target hoisted by Wells Fargo & Company from $22.00 to $30.00 in a research report released on Thursday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other brokerages have also recently weighed in on GLUE. Jefferies Financial Group reaffirmed a “buy” rating and issued a $31.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Guggenheim lifted their price target on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday. Zacks Research raised Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Finally, Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.20.

Monte Rosa Therapeutics Trading Down 4.1%

Shares of GLUE stock opened at $24.28 on Thursday. Monte Rosa Therapeutics has a twelve month low of $3.50 and a twelve month high of $25.77. The stock has a fifty day simple moving average of $16.01 and a two-hundred day simple moving average of $9.78. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 75.88 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. Research analysts predict that Monte Rosa Therapeutics will post -1.49 EPS for the current fiscal year.

Insider Activity at Monte Rosa Therapeutics

In other news, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the sale, the chief executive officer owned 618,937 shares of the company’s stock, valued at $14,538,830.13. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Monte Rosa Therapeutics in the fourth quarter worth about $271,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Monte Rosa Therapeutics by 20.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,289 shares of the company’s stock valued at $357,000 after acquiring an additional 3,746 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at approximately $30,000. Vestal Point Capital LP acquired a new stake in Monte Rosa Therapeutics in the 3rd quarter worth approximately $5,928,000. Finally, Scientech Research LLC purchased a new stake in Monte Rosa Therapeutics during the 3rd quarter worth approximately $120,000. 79.96% of the stock is owned by institutional investors and hedge funds.

More Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.